Clinical and Molecular Study of the *NOG* Gene in Families with Mandibular Micrognathism

Sandra J. Gutiérrez-Prieto¹ Diana M. Torres-López² Dabeiba A. García-Robayo¹
Jorge A. Rey-Cubillos³ Mariluz Gómez-Rodríguez⁴

¹Department of Dental System, Department of Oral System, Center for Dental Research, School of Dentistry, Pontificia Universidad Javeriana, Bogotá, Colombia

²Institute for Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia

³Postgraduate Department, School of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia

⁴Department of Natural Sciences and Mathematics, School of Engineering and Sciences, Pontificia Universidad Javeriana Cali, Cali, Colombia

Address for correspondence Sandra J. Gutiérrez-Prieto, Pontificia Universidad Javeriana, School of Dentistry, Center for Dental Research, 4th Floor, Carrera 7 # 40-62 Bogotá 110211, Colombia (e-mail: s.gutierrez@javeriana.edu.co).

Eur J Dent 2021;15:746–754.

Abstract

Objectives Previous studies showed that *noggin* gene (*NOG*) sequence alterations, as well as epigenetic factors, could influence mandibular development. The aim of this study was to analyze clinical characteristics, *NOG* gene sequences, and promoter methylation sites in patients with mandibular micrognathism.

Materials and Methods A total of 35 individuals of five Colombian families were subject to clinical and cephalometric analysis for mandibular micrognathism. One nonaffected individual of each family was included as a control. DNA was isolated from whole blood sample from all individuals by salting out method. Nine *NOG* gene fragments were amplified by polymerase chain reaction (PCR) and sequenced. Identification of CpG islands for methylation analysis at the *NOG* gene promoter was performed by MSP-PCR kit (Qiagen R).

Statistical Analysis A descriptive statistical analysis was carried out evaluating the presence or absence of genetics variants and the methylation sites in the *NOG* gene.

Results *NOG* sequence results of affected individuals with mandibular micrognathism for one of the families studied demonstrated that they were heterozygous for 672 C/A (new mutation). For a second family, individuals were heterozygous for 567 G/C (single nucleotide polymorphism [SNP] RS116716909). For DNA analyzed from all patients studied, no methylations were observed at the *NOG* gene promoter region.

Conclusion Our results suggested that 672 C/A and 567 G/C variants could be involved in the presence of mandibular micrognathism. Moreover, lack of methylation sites at the *NOG* gene promoter region of all individuals studied suggests possibly other epigenetic factors could modulate mandibular growth. The search of genetic variants related with mandibular micrognathism will allow to predict in an integral way the development patterns of the patients and therefore establish a better clinical treatment.

Keywords

- *noggin* gene
- mandibular micrognathism
- methylation
- bone morphogenic proteins

published online
September 30, 2021

DOI <https://doi.org/10.1055/s-0041-1726162>
ISSN 1305-7456.

© 2021. European Journal of Dentistry.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Introduction

One of the most frequent craniofacial malformations in the population is cleft palate and mandibular micrognathism,^{1,2} affecting the patients' quality of life.³ Mandibular micrognathism is characterized by the deficiency of mandible growth, which may be a cause of abnormal tooth alignment, not allowing for teeth to come in contact during mastication. Moreover, it interferes with the patient's phonation. In its severe form, micrognathism can be associated with sleep apnea^{4,5} and combined with glossoptosis and cleft palate (the isolated Pierre Robin sequence), it can obstruct the airways and thus result in difficulty of breathing.² Its etiology seems to include genetic factors, such as environmental, which are not well understood.⁶

Various studies demonstrate mandibular processes are composed of two independent functional regions, two large lateral processes depending on fibroblast growth factor (FGF)-8 signaling for development, and a small medial region independent of FGF-8. Therefore, mandible morphogenesis is characterized by a unique pattern of signaling molecules including bone morphogenetic protein-4 (BMP-4) and FGF-8.⁷⁻¹⁰ Bone morphogenetic proteins contribute with the formation of mandible components, yet they are implicated in other developmental processes, such as neurogenesis, joint and bone formation, and apoptosis of mesenchymal cells, at the joint site for the formation of synovial joint cavities.¹¹⁻¹⁵

This signaling pathway is regulated by various antagonists. Of these, the 232 amino acid (NP 005441) glycoprotein noggin,¹⁶ codified by the *NOG* gene located on chromosome 17q22 (*NOG*; MIM no.: 602991) that consists of a single 696 bp exon.¹⁷ Noggin modulates BMP signaling, preventing cell receptor binding, thus inhibiting signal transduction. By this mechanism, it modulates various signaling pathways during cartilage and bone formation in human development.^{16,17} *NOG* gene mutations results in BMP signaling alterations which leads to different types of dysplasias, such as proximal symphalangism (MIM 185800), which can be present with other phenotypic characteristic such as hemicylindrical nose configuration, hearing loss, as well as brachydactyly type 2 and synostosis type 1 (MIM 186500), among others.¹⁸⁻²¹

To date, some studies suggest *NOG* as a candidate for craniofacial disorders. A study performed in homozygous mice (*Nog*^{-/-}) revealed the absence of mandible development, mandibular hypoplasia, micrognathism, and agnathia. This study suggested *NOG* could act as an etiological factor in holoprosencephaly where mandibular micrognathism was evident.²² Gutiérrez et al²³ reported a possible association between 112 C > A (rs1348322) *NOG* exon 1 polymorphism with mandibular micrognathism in affected individuals in Colombian families. Likewise, significant associations have been identified between nonsyndromic cleft lip and palate and a single *NOG* nucleotide polymorphism (SNPs), suggesting that mutations in this gene could be relevant in mandible and palate development.²⁴⁻²⁷ Studies by Nimmagadda et al²⁸ established peptidase inhibitor (PI)-15 expressed in the frontonasal process, acted synergistically with *NOG* to induce maxillary and mandible cartilage, in addition to dental germ

formation. Studies other than genetic factors suggest that epigenetic factors contribute to BMP signaling, demonstrating it is possible to activate these signaling proteins through protein methylation via Smad6.²⁸⁻³⁰

The genotype-phenotype correlation of the *NOG* gene and mandibular micrognathism is still not very clear, and it is possible that there are also environmental factors that may be involved in its etiology. Therefore, the present work evaluated the presence of mutations in *NOG* gene in Colombian patients presenting mandibular micrognathism to establish a possible genotype-phenotype association and to carry out an initial exploration of the methylation sites in the promoter region of this gene to determine if there are possible epigenetic factors that may influence the etiology of this entity.

Materials and Methods

This project was approved by the ethics Committee School of Dentistry of the Pontificia Javeriana University (Minute 008 of 2011). The investigation was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki (2002). The population included five families with 35 individuals: 16 affected with mandibular micrognathism and 19 nonaffected individuals. All patients were examined by a physician at the School of Dentistry of the Pontificia Javeriana University. Informed consent was read and signed after the project was explained to each participant. A clinical genetic examination was performed to determine other phenotypes associated with a syndromic condition. Additionally, family trees were performed to determine inheritance patterns. Oral cavity examination was conducted, as well as oral photographs (front, profile, and smile). Moreover, profile and lateral cranial X-rays were performed to trace cephalometric measurements on them and determine presence of mandibular micrognathism (►Table 1).

DNA Extraction and Polymerase Chain Reaction Amplification

A 10-mL sample of peripheral blood was collected in Ethylenediaminetetraacetic (EDTA) tubes from each participant. DNA was extracted by salting out method³¹ and stored at 20°C before use. Nine fragments corresponding to 699 nucleotides *NOG* coding region, 437 nucleotides upstream, and 729 nucleotides downstream were amplified by polymerase chain reaction (PCR) using primers designed with PRIMER 3 program (<http://primer3.sourceforge.net/> ►Table 2). For PCR reactions, a master mix with a total volume of 25 µL was prepared, containing: 0.3 µL Taq DNA polymerase (Promega 5 µ/µL), 0.60 µL of each primer, 0.75 µL of dNTPs, 3 µL MgCl₂, 2.5 µL of 10 X Buffer (Promega, Madison, Wisconsin, United States) and 1 µL of DNA (50 ng/µL). Reaction was set up under the following conditions: initial denaturation at 95°C for 10 minutes; 35 cycles of denaturation at 94°C for 45 seconds, annealing temperature for each primer (►Table 2), and an extension at 72°C for 45 seconds (Bio-Rad Thermocycler, California, United States). A final extension was performed at 72°C for 7 minutes. Amplification product was verified in 1.5% agarose gel using ethidium bromide.

Table 1 Mandibular micrognathism cephalometric measurements for patient diagnosis

Mandible size	Distance (mm) from condylion (Co) to gnathion (Gn)—Bimler Peter	Distance (mm) from gonion (Go) to pogonion (Pg)—Legan and Burstone	Distance (mm) from point Xi to the point of intersection of line (Xi-Pm) and (A-Pg)—Ricketts Robert
Mandible ramus height	Distance (mm) from articular point (Ar) to Go point—Bimler Peter	Distance (mm) from Go point to the horizontal line (FH) on the plane (C-Go)—Legan and Burstone	Distance (mm) from CF to Go. Ricketts Robert
Maxillary ratios	Effective mean length, effective mandibular length (table of compound standards) ratio between maxillary length and mandibular length (Co-A) and (Co-Gn)—McNamara	Maxillary length, mandibular length. ratio between distance in mm (Co-A) and (Co-Gn)—Epker and Fish	
Chin size	Distance (mm) from the projection of point B to the tangent to Pg perpendicular to plane (Go-M)—Legan and Burstone		

Table 2 *NOG* gene codifying region amplification primers

Fragment	Forward primer	Reverse primer	Size	Annealing T (°C)
1	CCCCAGCCTAGGGGTAC	GTACAGCACGGGGCAGAAT	465	68
2	GCGAGATCAAAGGGCTAGAG	ATGGGGTACTGGATGGGAAT	319	59
3	GTCCAAGTCCGTGCACCT	GAAGCCGGTAACTTTTAACTGTA	394	59
4	CTGTGTAGGAATGTATATGTGTGTG	TCCTGCTCTGCACTTCTTTC	483	62
5	TTCTGGTTCTGTAAATGCACTG	CCCATCAATCACCAACACAG	399	62
6	GACCTCCGGCGGGTC	TTCTAGGGGCACTTCCCTC	450	64
7	CTGCGCGAAGGGCTC	CAGGACCACCACAGGG	220	64
8	CCCCAGCCTAGGGGTAC	TGTAATTCCTCCGAGCTT	426	59
9	GTGGGCAGCTGCTTCAGTA	GCGAAGGGCACTGGAATA	570	59

Abbreviation: *NOG*, noggin gene.**Table 3** *NOG* gene primers for methylation

<i>NOG</i> gene	Primer forward	Primer reverse
Methylated	5' GGTTAGGGGAGTCGTAGGC 3'	5' CTGGAACCCACGAAAAAATT3'
Non Methyl	5' GGGTTAGGGGAGTTGTAGGT 3'	5' CCTCAAACCCACAAAAAATT3'
Methylated 1	5' TATAGCGGGTTAGTAGAGGGC3'	5' CCTCAAAAACGCGACTAACT3'
Non Methyl 1	5' GTTTATAGTGGGTTAGTAGAGGG3	5' AACCTCAAAAACACAATACTC3

Abbreviation: *NOG*, noggin gene.

Sequencing

Amplified products were purified using a Wizard DNA purification system (Promega [Madison, Wisconsin, USA]), following the manufacturer's instructions. Furthermore, to establish the presence of mutations direct sequencing was performed in both directions. Sequencing was performed with ABI PRISM 310 automatic sequencer (Applied Biosystems, California, United States).

Methylation Analysis

DNA methylation was characterized according to identified CpG islands at *NOG* promoter region as reported in NCBI

database. MSP-PCR (Qiagen, Verlon, the Netherlands) kit was used with primers designed with METHYL PRIMER EXPRESS software (► **Table 3**). A master mix with a total volume of 15 µL contained 0.2 µL amplitaq (Promega 5 u/µL), 0.40 µL of each primer, 0.50 µL of dNTPs, 1.8 µL MgCl₂, 1.5 µL buffer (Promega), and 1 µL of DNA (50 ng/µL). Amplification conditions were initial denaturation at 95°C for 10 minutes; 35 cycles of denaturation at 94°C for 45 seconds, annealing temperature for each primer, and an extension at 72°C for 45 seconds (BioRad Thermocycler). A final extension was performed at 72°C for 7 minutes. The amplification product was verified in 1.5% agarose gel using ethidium bromide.

Results

Clinical Analysis

Out of 35 individuals from five different families, 16 were diagnosed with mandibular micrognathism. Patients from each family revealed similar characteristics with regard to class-II molar relationship, retrognathia position, maxillary shape, and length and hypodivergent skeletal pattern. Convex profile was the most common, as well as overjet increased. Upon clinical-genetic examination, none of the affected individuals examined manifested joint discomfort, bone, or finger abnormalities, as well as any syndromic alteration. A total of seven individuals, belonging to two families studied (family 1 and family 2) presented mutations in the *NOG* gene. The genealogical trees of both families suggested an autosomic dominant pattern of inheritance (►Figs. 1 and 2). Proband frontal and profile photographs from each of the two families displayed similar characteristics, despite belonging to different families and be of a different sex. Likewise, they presented similarities between their cephalometric measurements such as normal mandibular body length (Go-Pg), skeletal class II, decreased mandible, decreased posterior cranial base, increased anterior cranial base, retruded pogonion among others. The resulting cephalometric measurements Xi-Pm/Pg (mandibular size-Ricketts) and Co-Gn (mandibular length-MacNamara), of the affected individuals of both families were decreased confirming the diagnosis of mandibular micrognathism (►Tables 4 and 5).

Molecular Analysis

NOG Gene Sequence Variants and DNA Methylation

Results of noggin sequence (nine fragments) revealed that affected individuals with mandibular micrognathism belonged to family 1 and were heterozygous with a 672 C/A (new mutation) in *NOG* gene coding region (►Fig. 3A). Moreover, the affected individuals with mandibular micrognathism belonging to family 2 presented a heterozygous variant in *NOG* gene corresponding to 567 G/C 3' UTR (SNP RS116716909), previously reported by Zody et al³² (►Fig. 3B). Furthermore, all individuals analyzed for DNA methylation at *NOG* gene promotor lacked CH₃ group.

Discussion

The most identified mutations in exon 1 of *NOG* gene have been frequently associated with phenotypes, such as proximal symphalangism (SYM1; MIM no.: 185800) and other clinical spectra.^{18-21,33-38} Likewise, other studies have suggested the involvement of *NOG* gene in craniofacial disorders; including one performed in mice (*NOG*^{-/-}) which showed different phenotypes that range from hypertrophy to total lack of mandible or agnathia where micrognathism is somewhere in between.²²

In a previous study, we found a polymorphism reported in the National Center for Biotechnology Information (NCBI) SNP database and Ensembl (www.ncbi.nlm.nih.gov) in the *NOG* gene in Colombian patients with mandibular micrognathism, as an approximation of the possible role of this gene in

this malformation.²³ In the present study, two changes were identified; a new variant reported here (de novo mutation), consisting of a change from a cytosine to an adenine at nucleotide 672 (c.672C > A) in the coding region of the *NOG* gene (►Fig. 3A), and another reported in the literature corresponding to a change from guanine to a cytosine at nucleotide 567 (c.567G > C [rs116716909]³²; (►Fig. 3B). The variant c.567G > C (rs116716909), reported by Zody et al³² was identified in the 3' untranslated region (3'UTR) 567 nucleotides downstream of the stop codon. Until now, it had not been associated with any pathology nor with phenotypic characteristics since this variant was found in asymptomatic patients and no information is available in this regard.¹⁸

We found this polymorphic variant in a heterozygous form in individuals affected with mandibular micrognathism, belonging to one of the five families studied (family 2). This is the first time to report a possible association between this variant and mandibular micrognathism and its phenotypic characteristics are described (►Table 5). The results suggest that the region where this mutation is located doesn't generate severe phenotypes but could be altering *NOG* binding to BMP receptors. Therefore, inadequate signaling could be related to affected neural crest cell migration and proliferation, resulting possibly in mandibular

Fig. 1 Family 1. Genealogic tree suggested an autosomic dominant patterns (due the presence of a de novo mutation). Out of four individuals studied (*) in this family, three were affected by mandibular micrognathism. Patient III-2 corresponded to the proband (black arrow), patient II-3 to her mother, and the patient III.1 corresponded to the cousin also affected. The uncle (II-2) was the control used.

Fig. 2 Family 2. Genealogic tree shows autosomic dominant patterns. In this family four out of five individuals studied (*) were affected by mandibular micrognathism. Individual II-4 correspond to the proband (black arrow), patient I-1 to her mother, (health control).

Table 4 Cephalometric measurements of individuals diagnosed with mandibular micrognathism belonging to family 1 where a new variant 672 C/A in the *NOG* gene was found

Cephalometric measurement	Normal value (mm)	Individual /value III:2-F1 (proband-affected)	Individual /value II:3-F1 (affected)	Individual /value III:1-F1 (affected)
Go-Po (mm)	H: 83.7 ± 4.6 M: 74.3 ± 5.8	78	74	78
Xi-Pm/Pg Mandibular micrognathism according to McNamara cephalometry (mm)	81 ± 2.7	74	73	74
Ar-Go (mm)	H: 52 ± 4.2 M: 46.8 ± 2.5	35	48	55
CF-Go (mm)	62 ± 3.3	62	60	76
Co-A (mm)	H: 99.8 ± 4.3 M: 91 ± 6	91	90	96
Co-Gn Mandibular micrognathism according to McNamara cephalometry (mm)	H: 132.3 ± 6.8 M: 120.2 ± 5.3	114	112	114
Co-A/Co-Gn (mm)	H: 132.3 ± 6.8 M: 120.2 ± 5.3	22	22	22
B_I PM/Pg (mm)	H: 8.9 ± 1.7 M: 7.2 ± 1.9	7	7	5
Posterior skull base (mm)	H: 52.8 ± 4.1 M: 50.9 ± 3.0	35	29	38
Anterior skull base (mm)	H: 37.1 ± 2.8 M: 32.8 ± 1.9	53	51	51
Ba-Na/Ptm (degree)	H: 90 ± 3.5 M: 90 ± 3.2	106	90	95
Sn-Pm (degree)	32	52	33	33
Gl-Sn-Pog (degree)	12 ± 4	24	25	19
Gl (PH)-Sn (mm)	6 ± 3	0	1	3
Gl (PH)-Pog (mm)	0 ± 4	2	2	13
Gl-Sn/Sn-Me	101	80.83	72:65	66.81
Nasolabial (Cm-Sn-Ls) in degree	102 ± 8	108	98	109
Ls: Sn-Pog (mm)	3 ± 2 1	7	3	7
Li: Sn-Pog (mm)	2 ± 2 1	8	0	8
S. mentolabial (mm)	4 ± 2 2	4	2	4
Sn-STMs/STMi-Me	1:02	20:46:00	24:41:00	26:54:00
LE sup	4 mm n ± 2	2 mm	2 mmn	3 mm
LE inf	2 mm n ± 2	5 mm	3 mmn	5 mm
Facial morphological index		Leptoprosope	leptoprosope	Leptoprosope
Middle line facial symmetry		Asymmetry	Symmetry	Symmetry
Lip competition		Lip incompetence	Lip competence	Lip competence
Upper arch shape		Triangular	Oval	Oval
Lower arch shape		Oval	Oval	Oval

Abbreviations: Ar, articular; Co, condylion; Gn, gnathion; Go, gonion; *NOG*, noggin gene; Pg, pogonion; Xi, center point of the ascendig ramus of the mandible; Pm, chin bulge point; CF, center point of the face; Sn, subnasal; G, glabella; PH, horizontal plane; I, incisor; Ba, basion; Me, menton; Li, labrale inferior; Ls, labrale superios; STMs, stomion- upper maxillary (superior); STMi, stomion-lower maxillary (inferior); S, sella; LE sup-LE inf: (mm), line that goes from the tip of the nose to the (Me) point should be paralell to the upper and lower lip.

micrognathism. This variant seems to alter one of the cysteines at the position 192, an amino acid that has been shown to be necessary for *NOG* to fulfill its biological activities, such its binding to BMPs receptors through the formation of disulfide bonds or possible hydrogen bonds with other amino acids.³⁶

Even though various genetic association studies and chromosome 17 mapping of regions q22-q23, point out *NOG* as a gene that can be involved in various disorders, such as cleft-lip-palate^{24,25} and height alterations in humans,²⁷ none of these associated pathologies were observed in these

Table 5 Cephalometric measurements of individuals diagnosed with mandibular micrognathism belonging to family 2 where a reported variant c.567G > C (rs116716909) in the *NOG* gene was found

Cephalometric measurement	Normal value (mm)	Individual/ value II:4-F2 (proband-affected)	Individual/ valueI:2-F2 (affected)	Individual/ valueII:5-F2 (affected)	Individual/ valueII:3-F2 (affected)
Go-Po (mm)	H: 83.7 ± 4.6 M: 74.3 ± 5.8	76	73	76	75
Xi-Pm/Pg Mandibular micrognathism according to McNamara cephalometry (mm)	81 ± 2.7	77	77	77	73
Ar-Go (mm)	H: 52 ± 4.2 M: 46.8 ± 2.5	54	52	48	44
CF-Go (mm)	62 ± 3.3	63	73	62	57
Co-A (mm)	H: 99.8 ± 4.3 M: 91 ± 6	98	99	94	83
Co-Gn Mandibular micrognathism according to McNamara cephalometry (mm)	H: 132.3 ± 6.8 M: 120.2 ± 5.3	120	126	118	110
Co-A/Co-Gn (mm)	H: 132.3 ± 6.8 M: 120.2 ± 5.3	22	27	24	27
B_I PM/Pg (mm)	H: 8.9 ± 1.7 M: 7.2 ± 1.9	5	7	6	7
Posterior skull base (mm)	H: 52.8 ± 4.1 M: 50.9 ± 3.0	37	40	35	32
Anterior skull base (mm)	H: 37.1 ± 2.8 M: 32.8 ± 1.9	53	49	55	45
Ba-Na/Ptm (degree)	H: 90 ± 3.5 M: 90 ± 3.2	92	103	93	97
Sn-Pm (degree)	32	35	43	42	42
Gl-Sn-Pog (degree)	12 ± 4	22	20	26	30
Gl (PH)-Sn (mm)	6 ± 3	7	4	4	6
Gl (PH)-Pog (mm)	0 ± 4	4	13	12	1
Gl-Sn/Sn-Me	101	75.68	78:74	79.75	59.65
Nasolabial (Cm-Sn-Ls) in °C	102 ± 8	98	87	83	70
Ls: Sn-Pog (mm)	3 ± 2 1	7	7	8	8
Li: Sn-Pog (mm)	2 ± 2 1	7	7	5	7
S. mentolabial (mm)	4 ± 2 2	4	4	4	6
Sn-STMs/STMi-Me	1:02	23:45:00	28:47:00	24:50:00	21:44:00
LE sup	4 mm n ± 2	1 mm	1 mmn	1 mm	0 mm
LE inf	2 mm n ± 2	3 mm	2 mmn	0 mm	1 mm
Facial morphological index		Leptoprosope	leptoprosope	Leptoprosope	Leptoprosope
Middle line facial symmetry		Asymmetry	Asymmetry	Symmetry	Symmetry
Lip competition		Lip competence	Lip competence	Lip competence	Lip competence
Upper arch shape		Oval	square	Oval	Oval
Lower arch shape		Oval	Oval	Oval	Oval

Abbreviations: Ar, articular; Co, condylion; Gn, gnathion; Go, gonion; *NOG*, noggin gene; Pg, pogonion; Xi, center point of the ascending ramus of the mandible; Pm, chin bulge point; CF, center point of the face; Sn, subnasal; G, glabella; PH, horizontal plane; I, incisor; Ba, basion; Me, menton; Li, labrale inferior; Ls, labrale superior; STMs, stomion- upper maxillary (superior); STMi, stomion-lower maxillary (inferior); S, sella; LE sup-LE inf: (mm), line that goes from the tip of the nose to the (Me) point should be parallel to the upper and lower lip.

individuals. Furthermore, it is noteworthy that although at present most *NOG* mutations reported have been associated with symphalangism, bone problems, upper and lower limb

joints, it also, presents face anomalies, such as hemicylindrical nose, thin vermilion of the upper lip, and asymmetric mouth and other additional characteristics.³⁷ In the present

Fig. 3 (A) *NOG* gene change in the coding region from a Cytosine to an Adenine at nucleotide 672 (c.672C > A). This change found in *NOG* exon 1 gene was present in individuals III:2; III:1 and II-3 of Family 1, all affected with mandibular micrognathism. (B) *NOG* gene DNA sequencing profile in Family 2. Chromatogram of I-1 (control upper side) and Chromatogram of II-4 affected proband (lower side), which illustrates presence of heterozygous 567 G/C (SNP RS116716909) 3' UTR, polymorphism reported by Zody et al.³² All the affected with mandibular micrognathism presented this change. *NOG*, noggin gene.

study, this variant was identified, mandibular micrognathism was present, in addition to upper lip forward, facial asymmetry, convex profile, and low implantation of the outer ear were present without any evidence of hearing loss among others (►Table 5).

Upon genetic examination, the patients with this variant did not manifest any syndromic problem nor any evidence of characteristics affecting hand joints, knees or feet, or bone deformities. In line with that reported by Moffet et al,³⁹ who didn't find a significant association between *NOG* gene polymorphisms and bone phenotypes including osteoporosis.

The most mutations reported for *NOG* associated with symphalangism and bone alterations tend to be localized in regions affecting *NOG*'s capacity to bind to BMPs receptors,

thus presenting an ample spectrum of phenotypes.^{37,38} The polymorphic variant c.567G > C (rs116716909) presented in the individuals of family 2 of this study was located in the 3' UTR 567 nucleotides downstream of the stop codon³² (►Fig. 3B), and it is possible its location resulted in certain phenotypic characteristics, such as mandibular micrognathism, supporting the hypothesis proposed by Sha et al³⁵ where they suggested that certain phenotypes are associated with the exact localization of the mutation. It is probable for these individuals that the heterozygous sequence change exerted a very subtle effect on *NOG* gene (haploinsufficiency), slightly altering BMP signal modulation. Hence, they presented mandibular micrognathism without the accompanying severe bone characteristics.

In the present study, we also report a new heterozygous variant, consisting of a change from a cytosine to an adenine at nucleotide 672 (c.672C > A) in the coding region of *NOG* gene (►Fig. 3A) and was observed in three members of the family 1 (mother, daughter, and cousin) affected with mandibular micrognathism. The phenotypic characteristics of the members that presented this variant are depicted in ►Table 4. These were similar to the characteristics present by the members of the family 2, who present the c.567G > C (rs116716909) variant.

Although this new variant appears to be silent (change from one isoleucine to another isoleucine in the protein), the literature reports that these mutations may not be as silent as believed based on availability of transfer RNA (RNAt). If it exists in a small quantity to transport amino acids, translation is delayed and slows down which may result in less expression of the particular gene that contains the silent mutation in its coding region. Additionally, it seems that at any given time due to the delay in receiving the amino acid, the ribosome could terminate the translation prematurely.^{40,41} This could be one of the reasons why this phenotype may occur in this family, but protein functional studies with this variant must be performed.

Mother, daughter, and cousin affected with the new variant didn't evidence any osseous problems in knees, hands, or feet joints. In addition, upon clinical-genetic examination, they didn't present an associated syndrome, in line with reports in the literature, where substitution variants in the *NOG* gene, such as c.385C > A (rs117249328),³² c.520G. A (N/A), and c.73G4A(N/A)³⁵ didn't present any osseous characteristics, such as osteoporosis, symphalangism, or decreased mineralization.⁴²

On the other hand, to date, there are no reports associated to DNA methylation pattern alterations with mandibular disorders. The present study is a first approximation on *NOG* gene methylation patterns, with the objective of determining a possible cause for mandibular micrognathism in these patients that would be unrelated to DNA sequence alterations. However, in the sample studied no CH₃ groups were observed in the promoter region, which could suggest that no alterations in *NOG* promoter DNA methylation patterns in these studied individuals that could be associated with mandibular alterations and that other epigenetic factors could modulate mandibular growth. Studies are necessary that provide more evidence in this regard.

Conclusion

The results of this study showed the presence of two variants of the *NOG* gene and their phenotypic characteristics in patients with mandibular micrognathism, representing an important step toward the understanding of the genetic component of this disorder, and indicating the possible involvement of this gene in isolated mandibular micrognathism. However, it would be recommended for the respective tests to be performed for the diagnosis of mandibular micrognathism in patients with bone alterations, among

these symphalangism, to determine if in these patients this alteration also manifests.

On the other hand, the fact that these two different variants present in the *NOG* gene may be involved in the same phenotype with similar characteristics in two different families could suggest the existence of allelic heterogeneity which is attributable to genetic and/or environmental factors. This first study of DNA methylation in the *NOG* gene in this group of individuals with mandibular micrognathism showed the absence of methyl groups in *NOG*'s gene promoter region in blood cells, which could correspond to a pleiotropic role of *NOG*, since this gene participates in transforming growth factor (TGF)- β superfamily signaling inactivating BMP-4 and acting as a morphogen responsible of gradient expression in the differentiation of tissues during embryological development and tissue homeostasis.

The fact of not having found methylated sites in the *NOG* promoter region in this population under study can give us an approximation that the cause of this phenotype does not seem to be related to the inhibition of gene expression due to the presence of methylated sites in the promoter region, and that other environmental factors could be involved.

Finally, the studies of the presence of *NOG* gene variants could help predict alterations, such as skeletal class II in families, which traditionally has been estimated from the correlation between the phenotypes of parents and their offspring or the comparison of phenotypes between monozygotic twin pairs (MZ) and dizygotic (DZ). It is essential that dental professionals, especially orthodontists, consider the genetic factors that are influencing more frequent in the developmental alterations in the population and how this will contribute to the diagnostic and successful management of their patients, including new therapies, where the possibility of gene therapy can be contemplated in the near future.

Funding

This project was financed by Pontificia Javeriana University, grant no: 4397 and 9217.

Conflict of Interest

None declared.

Acknowledgment

Authors would like to thank Pontificia Javeriana University for their support.

References

- 1 Mossey PA, Modell B. Epidemiology of oral cleft: an international perspective. In: Wyszynski DF, ed. Cleft lip and palate. From Origin to Treatment. New York, NY: Oxford University Press; 2002
- 2 Holder-Espinasse M, Abadie V, Cormier-Daire V, et al. Pierre Robin sequence: a series of 117 consecutive cases. *J Pediatr* 2001;139(4):588–590
- 3 Pruzinsky T. Social and psychological effects of major craniofacial deformity. *Cleft Palate Craniofac J* 1992;29(6):578–584, discussion 570

- 4 Chigurupati R, Massie J, Dargaville P, Heggie A. Internal mandibular distraction to relieve airway obstruction in infants and young children with micrognathia. *Pediatr Pulmonol* 2004;37(3):230–235
- 5 Martínez-Plaza A, Martínez-Lara I, García-Medina B, Fernández- Valadés R. Distracción ósea: tratamiento de la apnea obstructiva en neonatos con micrognatia. *Rev Esp Cir Oral Maxilofac* 2011;33(2):67–74
- 6 Yu S, Tang Q, Xie M, et al. Circadian BMAL1 regulates mandibular condyle development by hedgehog pathway. *Cell Prolif* 2020;53(1):e12727
- 7 Mina M, Wang YH, Ivanisevic AM, Upholt WB, Rodgers B. Region- and stage-specific effects of FGFs and BMPs in chick mandibular morphogenesis. *Dev Dyn* 2002;223(3):333–352
- 8 Tucker AS, Yamada G, Grigoriou M, Pachnis V, Sharpe PT. Fgf-8 determines rostral-caudal polarity in the first branchial arch. *Development* 1999;126(1):51–61
- 9 Shigetani Y, Nobusada Y, Kuratani S. Ectodermally derived FGF8 defines the maxillomandibular region in the early chick embryo: epithelial-mesenchymal interactions in the specification of the craniofacial ectomesenchyme. *Dev Biol* 2000;228(1):73–85
- 10 Ferguson CA, Tucker AS, Sharpe PT. Temporospatial cell interactions regulating mandibular and maxillary arch patterning. *Development* 2000;127(2):403–412
- 11 Ekanayake S, Hall BK. The in vivo and in vitro effects of bone morphogenetic protein-2 on the development of the chick mandible. *Int J Dev Biol* 1997;41(1):67–81
- 12 Kanzler B, Foreman RK, Labosky PA, Mallo M. BMP signaling is essential for development of skeletogenic and neurogenic cranial neural crest. *Development* 2000;127(5):1095–1104
- 13 Bonilla-Claudio M, Wang J, Bai Y, Klysik E, Selever J, Martin JF. Bmp signaling regulates a dose-dependent transcriptional program to control facial skeletal development. *Development* 2012;139(4):709–719
- 14 Brunet LJ, McMahon JA, McMahon AP, Harland RM. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. *Science* 1998;280(5368):1455–1457
- 15 McMahon JA, Takada S, Zimmerman LB, Fan CM, Harland RM, McMahon AP. Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. *Genes Dev* 1998;12(10):1438–1452
- 16 Zimmerman LB, De Jesús-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. *Cell* 1996;86(4):599–606
- 17 Valenzuela DM, Economides AN, Rojas E, et al. Identification of mammalian noggin and its expression in the adult nervous system. *J Neurosci* 1995;15(9):6077–6084
- 18 Potti TA, Petty EM, Lesperance MM. A comprehensive review of reported heritable noggin-associated syndromes and proposed clinical utility of one broadly inclusive diagnostic term: NOG-related-symphalangism spectrum disorder (NOG-SSD). *Hum Mutat* 2011;32(8):877–886
- 19 Gong Y, Krakow D, Marcelino J, et al. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. *Nat Genet* 1999;21(3):302–304
- 20 Masuda S, Namba K, Mutai H, et al. A mutation in the heparin-binding site of noggin as a novel mechanism of proximal symphalangism and conductive hearing loss. *Biochem Biophys Res Commun* 2014;447(3):496–502
- 21 Sémonin O, Fontaine K, Daviaud C, Ayuso C, Lucotte G. Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressiva. *Am J Med Genet* 2001;102(4):314–317
- 22 Anderson RM, Lawrence AR, Stottmann RW, Bachiller D, Klingensmith J. Chordin and noggin promote organizing centers of forebrain development in the mouse. *Development* 2002;129(21):4975–4987
- 23 Gutiérrez SJ, Gómez M, Rey JA, Ochoa M, Gutiérrez SM, Prieto JC. Polymorphisms of the noggin gene and mandibular micrognathia: a first approximation. *Acta Odontol Latinoam* 2010;23(1):13–19
- 24 Song T, Shi J, Guo Q, et al. Association between NOGGIN and SPRY2 polymorphisms and nonsyndromic cleft lip with or without cleft palate. *Am J Med Genet A* 2015;167A(1):137–141
- 25 Mangold E, Ludwig KU, Birnbaum S, et al. Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. *Nat Genet* 2010;42(1):24–26
- 26 Setó-Salvia N, Stanier P. Genetics of cleft lip and/or cleft palate: association with other common anomalies. *Eur J Med Genet* 2014;57(8):381–393
- 27 Gudbjartsson DF, Walters GB, Thorleifsson G, et al. Many sequence variants affecting diversity of adult human height. *Nat Genet* 2008;40(5):609–615
- 28 Nimmagadda S, Buchtová M, Fu K, et al. Identification and functional analysis of novel facial patterning genes in the duplicated beak chicken embryo. *Dev Biol* 2015;407(2):275–288
- 29 Garrick D, Fiering S, Martin DI, Whitelaw E. Repeat-induced gene silencing in mammals. *Nat Genet* 1998;18(1):56–59
- 30 Xu J, Wang AH, Osés-Prieto J, et al. Arginine methylation initiates BMP-induced Smad signaling. *Mol Cell* 2013;51(1):5–19
- 31 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988;16(3):1215
- 32 Zody MC, Garber M, Adams DJ, et al. DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. *Nature* 2006;440(7087):1045–1049
- 33 Marcelino J, Sciortino CM, Romero MF, et al. Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. *Proc Natl Acad Sci U S A* 2001;98(20):11353–11358
- 34 Takano K, Ogasawara N, Matsunaga T, et al. A novel nonsense mutation in the NOG gene causes familial NOG-related symphalangism spectrum disorder. *Hum Genome Var* 2016;3:16023
- 35 Sha Y, Ma D, Zhang N, Wei X, Liu W, Wang X. Novel NOG (p.P42S) mutation causes proximal symphalangism in a four-generation Chinese family. *BMC Med Genet* 2019;20(1):133
- 36 Liu WD, Feng XL, Ren CP, et al. Critical role of Cys168 in noggin protein's biological function. *Acta Biochim Biophys Sin (Shanghai)* 2005;37(3):181–185
- 37 Higashi K, Inoue S. Conductive deafness, symphalangism, and facial abnormalities: the WL syndrome in a Japanese family. *Am J Med Genet* 1983;16(1):105–109
- 38 Dąbrowska M, Dąbrowski P, Tabarkiewicz J. Fibrodysplasia Ossificans Progressiva – a presentation of cases and literature review. *European J of Clin and Experim Med*. 2019;2:184–191
- 39 Moffett SP, Dillon KA, Yerges LM, et al. Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes. *Bone* 2009;44(5):999–1002
- 40 Angov E. Codon usage: nature's roadmap to expression and folding of proteins. *Biotechnol J* 2011;6(6):650–659
- 41 Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P.W. *Molecular Biology of the Cell*. 4th ed. New York, NY: Garland Science; 2007
- 42 Yerges LM, Klei L, Cauley JA, et al. High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men. *J Bone Miner Res* 2009;24(12):2039–2049